Therefore, by expressing HSVtk under the FOS promoter, we demonstrated selective inhibition of cancer cells, a crucial requirement for the establishment of Ad-FOS-HSVtk as a potential therapeutic agent for glioma. This evidence concerns the gene FOS and glioma.